Many other mechanisms of laptatinib resistance have been investigated [134,140,141,142,143,144], however the authors of this study suggest that PP2A has potential as a novel biomarker of lapatinib resistance and PP2A inhibition in combination with HER2 inhibition merits further investigation as a potential therapy for this type of breast cancer [138]. This evidence concerns the gene ERBB2 and breast cancer.